Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Migraine

Free Subscription Articles published in Headache Retrieve available abstracts of 362 articles: HTML format

Single Articles

March 2026
1. HIKITA T, Kudo T, Ogawa Y, Nakamoto N, et al
   A study of migraine-like headache caused by topical aryl hydrocarbon receptor agonist tapinarof.
   Headache. 2026 Mar 6. doi: 10.1111/head.70077.
   PubMed    
   
   
   
2. DORSEY E, Robblee J
   Epidemiology and characteristics of status migrainosus in a tertiary headache clinic: A retrospective cohort study.
   Headache. 2026 Mar 6. doi: 10.1111/head.70067.
   PubMed     Abstract available
   
   
   
3. SILBERSTEIN S, Rapoport AM
   Novel optimization of multi-mechanistic approaches for the acute treatment of a migraine attack: A review.
   Headache. 2026 Mar 4. doi: 10.1111/head.70051.
   PubMed     Abstract available
   
   
   
4. TOL CHM, Visscher CM, van der Wal AC, Su N, et al
   Psychosocial factors as predictors of headache chronification: A systematic review and meta-analysis of longitudinal studies.
   Headache. 2026;66:755-767.
   PubMed     Abstract available
   
   
   
5. ZAVALA LJ, Gil Ramirez A, Vetvik KG, Jensen RH, et al
   Headache in individuals undergoing hormone therapy for gender transition: A cross-sectional, observational study.
   Headache. 2026;66:725-732.
   PubMed     Abstract available
   
   
   February 2026
6. HUTCHINSON S, Johnston E, Nicholson RA, Reed ML, et al
   Unmet treatment needs in migraine: Results of the OVERCOME (US) study.
   Headache. 2026 Feb 20. doi: 10.1111/head.70043.
   PubMed     Abstract available
   
   
   
7. YANG PH, Zhang N, Chao CJ, Lopez-Jimenez F, et al
   Higher artificial intelligence-ECG atrial fibrillation prediction model output and estimated physiologic aging predict higher risk of adverse vascular events in patients with migraine.
   Headache. 2026 Feb 20. doi: 10.1111/head.70062.
   PubMed     Abstract available
   
   
   
8. LIPTON RB, Dodick DW, Davis L, Nahas SJ, et al
   Integrating gepants into clinical practice for the acute treatment of migraine.
   Headache. 2026 Feb 18. doi: 10.1111/head.70047.
   PubMed     Abstract available
   
   
   
9. NITSCHE L, Helbach J, Stubenrauch S, Lakeberg M, et al
   The association between posttraumatic stress disorder and migraine: A systematic review.
   Headache. 2026 Feb 18. doi: 10.1111/head.70058.
   PubMed     Abstract available
   
   
   
10. 
    Correction to "Migraine and air pollution: A systematic review".
    Headache. 2026 Feb 12. doi: 10.1111/head.70053.
    PubMed    
    
    
    
11. GRAVES KS, To J, Paige H, Kennedy AG, et al
    Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.
    Headache. 2026 Feb 12. doi: 10.1111/head.70057.
    PubMed     Abstract available
    
    
    
12. CHARLESTON L 4TH, Armand CE, Monteith TS, O'Brien HL, et al
    Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials.
    Headache. 2026 Feb 6. doi: 10.1111/head.70034.
    PubMed     Abstract available
    
    
    
13. TOURLAS K, Ilangovan S, White C, Irwin SL, et al
    Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents.
    Headache. 2026 Feb 6. doi: 10.1111/head.70033.
    PubMed     Abstract available
    
    
    
14. GERARD B, Praudel H, Lanteri-Minet M, Van Obberghen E, et al
    First successful protocol for desensitization to eptinezumab.
    Headache. 2026;66:556-559.
    PubMed     Abstract available
    
    
    January 2026
15. NWAOBI SE
    Useful considerations for treating migraine in patients with autism.
    Headache. 2026 Jan 29. doi: 10.1111/head.70054.
    PubMed    
    
    
    
16. CHEN H, Li Y
    Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Headache. 2026 Jan 28. doi: 10.1111/head.70049.
    PubMed     Abstract available
    
    
    
17. BUSE DC, Videnieks LA, Charles K, Lozach K, et al
    Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi-source dataset, observational cohort study.
    Headache. 2026 Jan 21. doi: 10.1111/head.70026.
    PubMed     Abstract available
    
    
    
18. AILANI J, Okonkwo R, Johnston E, Hochstetler H, et al
    Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study.
    Headache. 2026 Jan 6. doi: 10.1111/head.70014.
    PubMed     Abstract available
    
    
    
19. ZELDICH D, Calderon N, Goor-Aryeh I, Lichtenstein GR, et al
    Case report: Treatment of temporomandibular joint disorder pain with V3 nerve block procedure.
    Headache. 2026;66:332-335.
    PubMed     Abstract available
    
    
    
20. SHIN L, Mentz O, Gelfand AA, de Prado BM, et al
    Gepants for headache prevention in children and adolescents: A multicenter chart review study.
    Headache. 2026;66:239-248.
    PubMed     Abstract available
    
    
    
21. PATEL EJ, Sharon JD, Levin M, Luebke AE, et al
    Calcitonin gene-related peptide in the audiovestibular system.
    Headache. 2026;66:278-285.
    PubMed     Abstract available
    
    
    December 2025
22. CHENG N, Anderson CC, Zhang N, VanderPluym JH, et al
    Remote electrical neuromodulation for reducing procedural pain in patients with chronic migraine receiving onabotulinumtoxinA injections: A randomized sham-controlled study.
    Headache. 2025 Dec 31. doi: 10.1111/head.70032.
    PubMed     Abstract available
    
    
    
23. SCHUSTER NM, Wallace MS, Marcotte TD, Buse DC, et al
    Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.
    Headache. 2025 Dec 30. doi: 10.1111/head.70025.
    PubMed     Abstract available
    
    
    
24. GRANT TEJADA MP, Klomhaus AM, Ortiz R, Tibbe TD, et al
    Migraine prevalence and phenotype in autism: A retrospective cohort study using a US National Health Survey and large academic health system electronic health record.
    Headache. 2025 Dec 29. doi: 10.1111/head.70035.
    PubMed     Abstract available
    
    
    
25. SCHINDLER EAD, Gottschalk CH, Pittman BP, D'Souza DC, et al
    Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.
    Headache. 2025 Dec 29. doi: 10.1111/head.70024.
    PubMed     Abstract available
    
    
    
26. MEHNERT J, Scutelnic A
    Migraine is a disorder of function: No evidence for structural alterations within the central nervous system in migraine.
    Headache. 2025 Dec 16. doi: 10.1111/head.70010.
    PubMed    
    
    
    
27. PARDO K, Mermelstein M, Tsur G, Yust-Katz S, et al
    Do patients with migraine and obesity receive different treatments? Insights from real-world data.
    Headache. 2025 Dec 15. doi: 10.1111/head.70011.
    PubMed     Abstract available
    
    
    
28. BLUMENFELD AM, Charleston L 4th, Kuruvilla D, Savage-Edwards B, et al
    OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trial.
    Headache. 2025 Dec 15. doi: 10.1111/head.70007.
    PubMed     Abstract available
    
    
    
29. SCHWEDT TJ, Starling AJ, Ailani J, Hershey AD, et al
    Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society.
    Headache. 2025 Dec 10. doi: 10.1111/head.70023.
    PubMed     Abstract available
    
    
    
30. TANG Y, Lu C, Zhou Y, Qian S, et al
    Treatment of abdominal migraine in an 8-year-old child with calcitonin gene-related peptide receptor antagonist: A case report.
    Headache. 2025 Dec 10. doi: 10.1111/head.70017.
    PubMed    
    
    
    
31. GUNASEKERA L, Cheng S, Foster E, Sivathamboo S, et al
    A retrospective audit of the real-world safety and effectiveness profile of eptinezumab for treatment-resistant chronic migraine in Australia.
    Headache. 2025 Dec 2. doi: 10.1111/head.70015.
    PubMed     Abstract available
    
    
    
32. ROBBLEE J, Minen MT, Friedman BW, Cortel-LeBlanc MA, et al
    2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
    Headache. 2025 Dec 1. doi: 10.1111/head.70016.
    PubMed     Abstract available
    
    
    November 2025
33. MUNOZ-VENDRELL A, Campoy-Diaz S, Diaz-Corta P, Termens L, et al
    False nonresponders to anti-calcitonin gene-related peptide monoclonal antibodies: A real-world analysis beyond migraine frequency reduction.
    Headache. 2025 Nov 28. doi: 10.1111/head.70012.
    PubMed     Abstract available
    
    
    
34. ZHAO SJ, Wang TT, Zhang Q, Akerman S, et al
    The role of stress in the comorbidity of migraine and other chronic primary pain.
    Headache. 2025 Nov 26. doi: 10.1111/head.70004.
    PubMed     Abstract available
    
    
    
35. LYSK S, Pach D, Tissen-Diabate T, Scholler S, et al
    Engagement and predictors of use of a smartphone app for migraine self-management: A secondary analysis of the EMMA trial.
    Headache. 2025 Nov 25. doi: 10.1111/head.70009.
    PubMed     Abstract available
    
    
    
36. EL AHDAB J, Vilardo M, Ong B, Thompson NR, et al
    The effect of vestibular rehabilitation in the management of vestibular migraine in adults: A systematic review and meta-analysis.
    Headache. 2025 Nov 25. doi: 10.1111/head.70002.
    PubMed     Abstract available
    
    
    
37. GAUL C, Ferreira S, Johansen T
    Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double-blind, randomized, controlled trial (PAREMA1).
    Headache. 2025 Nov 21. doi: 10.1111/head.15090.
    PubMed     Abstract available
    
    
    
38. FERNANDEZ-BRAVO-RODRIGO J, Pascual-Morena C, Saz-Lara A, Martinez-Garcia I, et al
    Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.
    Headache. 2025 Nov 17. doi: 10.1111/head.70003.
    PubMed     Abstract available
    
    
    
39. KITAMURA S, Matsumori Y, Yamamoto T, Ishikawa T, et al
    Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
    Headache. 2025 Nov 17. doi: 10.1111/head.15095.
    PubMed    
    
    
    
40. CHAUDHRY BA, Christensen RH, Ashina H, Al-Khazali HM, et al
    No differences in subcortical volume between people with and without migraine: A REFORM study.
    Headache. 2025 Nov 14. doi: 10.1111/head.70001.
    PubMed     Abstract available
    
    
    
41. DE OLIVEIRA AB, Santos IS, Peres MFP, Conforto AB, et al
    Sex-specific differences in the relationship between AHA Life's Essential 8 factors and migraine disorders: A cross-sectional evaluation in ELSA-Brasil study.
    Headache. 2025 Nov 13. doi: 10.1111/head.15089.
    PubMed     Abstract available
    
    
    
42. SZABO E, Gelfand AA
    Virtual issue: Real-world studies in migraine.
    Headache. 2025 Nov 6. doi: 10.1111/head.15088.
    PubMed    
    
    
    
43. VILLARUZ RH, Kuziek J, Sjonnesen K, Craddock L, et al
    Chinook winds and migraine attack onset in children and adolescents: A prospective longitudinal clinical cohort study.
    Headache. 2025 Nov 5. doi: 10.1111/head.15093.
    PubMed     Abstract available
    
    
    
44. AILANI J, Charleston L 4th, Strom S, Albrecht D, et al
    Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study.
    Headache. 2025 Nov 4. doi: 10.1111/head.15086.
    PubMed     Abstract available
    
    
    
45. WIELAND S, Emborg MS, de Wolff MG, Damm P, et al
    Use of antimigraine medication before pregnancy and in the first trimester: A cross-sectional study.
    Headache. 2025;65:1704-1715.
    PubMed     Abstract available
    
    
    
46. GARELJA ML, Rees TA, Hay DL
    Calcitonin gene-related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme-linked immunosorbent assays.
    Headache. 2025;65:1744-1753.
    PubMed     Abstract available
    
    
    October 2025
47. MORENO-AJONA D
    Persistent postural-perceptual dizziness versus vestibular migraine: A narrative review.
    Headache. 2025 Oct 28. doi: 10.1111/head.15078.
    PubMed     Abstract available
    
    
    
48. NIU H, Robblee J
    Migraine in disguise: How over-the-counter medication labeling perpetuates the "sinus headache" myth.
    Headache. 2025 Oct 28. doi: 10.1111/head.15092.
    PubMed    
    
    
    
49. KARSAN N, Vandenbussche N, Jenia-Wilcha R, Amarasena P, et al
    Evaluating associations of migraine-related vertigo.
    Headache. 2025 Oct 26. doi: 10.1111/head.15038.
    PubMed     Abstract available
    
    
    
50. WOLDEAMANUEL YW
    Editorial: Rethink your exercise for precision migraine management.
    Headache. 2025 Oct 26. doi: 10.1111/head.15077.
    PubMed    
    
    
    
51. LIM CN, Mo G, Bhardwaj R, Comisar CM, et al
    A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged >/=6 to <12 years) with a history of migraine.
    Headache. 2025 Oct 24. doi: 10.1111/head.15074.
    PubMed     Abstract available
    
    
    
52. BAR M, Peles I, Ifergane G, Tsumi E, et al
    The association between migraine and glaucoma diseases: A retrospective cohort study.
    Headache. 2025 Oct 24. doi: 10.1111/head.15079.
    PubMed     Abstract available
    
    
    
53. REDUCHA PV, Nielsen LKS, Jensen MN, Edvinsson JCA, et al
    TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms.
    Headache. 2025 Oct 24. doi: 10.1111/head.15082.
    PubMed     Abstract available
    
    
    
54. OLIVEIRA DA SILVA R, Mendes Filho FSM, Pedrosa JGG, Pascual GS, et al
    Efficacy and tolerability of erenumab for chronic migraine in association with medication overuse: A systematic review and meta-analysis.
    Headache. 2025 Oct 22. doi: 10.1111/head.15068.
    PubMed     Abstract available
    
    
    
55. QAISER S, Shady K
    Serum magnesium levels in children and adolescents with migraine: A prospective observational study.
    Headache. 2025 Oct 16. doi: 10.1111/head.15081.
    PubMed    
    
    
    
56. NAHAS SJ, Birlea M, Stark-Inbar A, Shmuely S, et al
    Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon.
    Headache. 2025 Oct 16. doi: 10.1111/head.15069.
    PubMed     Abstract available
    
    
    
57. GRODZKA O, Boronczyk M, Zdunska A, Wegrzynek-Gallina J, et al
    Migraine and patent foramen ovale: correlation, coexistence, dependence. A narrative review.
    Headache. 2025 Oct 15. doi: 10.1111/head.15067.
    PubMed     Abstract available
    
    
    
58. PERIS-SUBIZA J, Obach V, Guisado-Alonso D, Velasco Juanes F, et al
    Effectiveness and tolerability of galcanezumab for migraine prevention in patients >/=65 years: A real-life multicenter study.
    Headache. 2025 Oct 14. doi: 10.1111/head.15064.
    PubMed     Abstract available
    
    
    
59. OGREZEANU DC, Nunez-Cortes R, Salazar-Mendez J, Cuyul-Vasquez I, et al
    How much aerobic exercise is needed to reduce migraine? A dose-response meta-analysis of pain intensity and frequency.
    Headache. 2025 Oct 14. doi: 10.1111/head.15070.
    PubMed     Abstract available
    
    
    
60. PAIVA DA SILVA LIMA G, Rao R, Szabo G, Szklener S, et al
    Comprehensive assessment of erenumab efficacy in participants with high-frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study.
    Headache. 2025 Oct 14. doi: 10.1111/head.15071.
    PubMed     Abstract available
    
    
    
61. WELLS RE, Floyd J, O'Brien H, Tamol N, et al
    Building a national headache medicine research network: The BE WELL with Migraine Champion Providers Network.
    Headache. 2025 Oct 9. doi: 10.1111/head.15065.
    PubMed     Abstract available
    
    
    
62. NEWMAN LC, Lay C, Lipton RB, Ailani J, et al
    Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper.
    Headache. 2025 Oct 3. doi: 10.1111/head.15062.
    PubMed     Abstract available
    
    
    September 2025
63. LIPTON RB, Lainez MJA, Ahmed Z, Vallarino C, et al
    Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study.
    Headache. 2025 Sep 29. doi: 10.1111/head.15045.
    PubMed     Abstract available
    
    
    
64. LA N, Rattanapitoon SK, Rattanapitoon NK
    Cardiovascular risk considerations in triptan therapy for migraine: Reflections on the study by Peles et al.
    Headache. 2025 Sep 22. doi: 10.1111/head.15063.
    PubMed    
    
    
    
65. LEE KH, Liang CS, Yeh PK, Tsai CK, et al
    Insomnia severity in migraine: The role of headache frequency, aura status, and comorbidities-A cross-sectional study.
    Headache. 2025 Sep 19. doi: 10.1111/head.15055.
    PubMed     Abstract available
    
    
    
66. O'HARE L, Hibbard PB, Wilkins AJ
    Evidence for increased background neural noise in migraine with aura: Hyperactive but not hyperresponsive.
    Headache. 2025 Sep 16. doi: 10.1111/head.15046.
    PubMed     Abstract available
    
    
    
67. GOMEZ-DABO L, Gallardo VJ, Campos-Fernandez D, Rodrigo-Gisbert M, et al
    Persistent headache after aneurysmal subarachnoid hemorrhage: Prevalence, characteristics, and migraine history as a prognostic factor.
    Headache. 2025 Sep 15. doi: 10.1111/head.15052.
    PubMed     Abstract available
    
    
    
68. CHARLES AC, Tepper SJ, Ailani J
    State of the art in the management of migraine-A response to the American College of Physicians migraine preventive treatment guideline.
    Headache. 2025 Sep 11. doi: 10.1111/head.15051.
    PubMed    
    
    
    
69. DE DHAEM OB, Verhaak A, Fajardo M, Grosberg B, et al
    Migraine in the workplace: Work productivity impact in a large US-based healthcare system using a cross-sectional employee survey.
    Headache. 2025 Sep 8. doi: 10.1111/head.15053.
    PubMed     Abstract available
    
    
    
70. 
    Correction to "Smartphone-delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial".
    Headache. 2025 Sep 3. doi: 10.1111/head.14939.
    PubMed    
    
    
    
71. ESPANIOLI A, van den Hoogen NJ, Kuziek J, Sjonnesen K, et al
    Exploring the relationship between pain catastrophizing and migraine in youth: A longitudinal clinical cohort study.
    Headache. 2025 Sep 1. doi: 10.1111/head.15039.
    PubMed     Abstract available
    
    
    
72. LIPTON RB, Stokes J, Evans CJ, Hribal E, et al
    Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing.
    Headache. 2025 Sep 1. doi: 10.1111/head.15024.
    PubMed     Abstract available
    
    
    
73. EZZATI A, Fanning KM, Teichrow D, Urani A, et al
    Headache Assessment via Digital Platform in United States: Baseline study characteristics, diagnosis, and treatment patterns.
    Headache. 2025;65:1428-1438.
    PubMed     Abstract available
    
    
    August 2025
74. YOO A, Keenan B, Vgontzas A, Mittleman MA, et al
    Waning light, waxing pain: The lunar cycle's association with migraine headache occurrence.
    Headache. 2025 Aug 28. doi: 10.1111/head.15035.
    PubMed     Abstract available
    
    
    
75. FISHBEIN JN, Schuster NM, Anders A, Portera AM, et al
    Pain Reprocessing Therapy for migraine: A case series.
    Headache. 2025 Aug 27. doi: 10.1111/head.15043.
    PubMed     Abstract available
    
    
    
76. UNIYAL R, Garg RK, Verma R, Paliwal VK, et al
    Author response to comments on our article "Impact of perilesional edema on severity of migraine in patients with calcified neurocysticercosis: A prospective evaluation".
    Headache. 2025 Aug 26. doi: 10.1111/head.15029.
    PubMed    
    
    
    
77. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor regarding "Impact of perilesional edema on severity of migraine in patients with calcified neurocysticercosis: A prospective evaluation".
    Headache. 2025 Aug 26. doi: 10.1111/head.15036.
    PubMed    
    
    
    
78. YE S, Gao Y, Lin Y, Wang J, et al
    Ambient nitrogen dioxide, temperature exposure, and migraine incidence: A large prospective cohort study.
    Headache. 2025 Aug 26. doi: 10.1111/head.15037.
    PubMed     Abstract available
    
    
    
79. LIANG J, Yang L, Yang Q, Zhang Y, et al
    Lessons from the coronavirus disease 2019 pandemic: Investigating the bidirectional relationship between coronavirus disease 2019 and migraine based on the MECH-HK cohort study.
    Headache. 2025 Aug 22. doi: 10.1111/head.15040.
    PubMed     Abstract available
    
    
    
80. ORNELLO R, Salfi F, Vittorini MG, Innocenzi A, et al
    The potential role of sleep quality in the relationship between glymphatic function and migraine frequency: Insights from a cross-sectional study.
    Headache. 2025 Aug 19. doi: 10.1111/head.15019.
    PubMed     Abstract available
    
    
    
81. GETZ M, Charleston L 4th, Armand CE, Willis AW, et al
    Plain Language Summary Publication: Perceived discrimination and migraine-specific quality of life: A cross-sectional survey study in a Black/African American sample.
    Headache. 2025 Aug 8. doi: 10.1111/head.15028.
    PubMed    
    
    
    
82. YANG F, Tian X, Xu Y, Yang S, et al
    A machine learning-driven transcriptomic study reveals the key role of Romo1 in reversing central sensitization through stellate ganglion block in migraine: An interventional study based on a recurrent migraine rat model.
    Headache. 2025 Aug 1. doi: 10.1111/head.14997.
    PubMed     Abstract available
    
    
    July 2025
83. XIE S, Huo Y, Geng X, Hu L, et al
    Exploring the alterations in microstate dynamics during the migraine cycle and detecting pre-ictal phases.
    Headache. 2025 Jul 31. doi: 10.1111/head.15031.
    PubMed     Abstract available
    
    
    
84. MANGANO GD, Antona V, Santangelo G, Di Pasquale G, et al
    A novel de novo AP2M1 variant in a patient with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and unexpected hemiplegic migraine.
    Headache. 2025 Jul 28. doi: 10.1111/head.15017.
    PubMed    
    
    
    
85. RAQUIN M, Mrad Y, Zkim MA, Dallel R, et al
    Sex influences the progression of cephalic mechanical and light hypersensitivities in a mouse model of chronic migraine.
    Headache. 2025 Jul 25. doi: 10.1111/head.15015.
    PubMed     Abstract available
    
    
    
86. VILA-PUEYO M, Goadsby PJ, Johnson KW, Holland PR, et al
    Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgias.
    Headache. 2025 Jul 21. doi: 10.1111/head.15006.
    PubMed     Abstract available
    
    
    
87. DEMIRSOY I, Lipton RB, Ezzati A
    Real-world barriers to health care utilization among people living with migraine: Insights from the All of Us Research Program.
    Headache. 2025 Jul 15. doi: 10.1111/head.15007.
    PubMed     Abstract available
    
    
    
88. FREIMARK G, Strauss S, Overeem LH, Fitzek MP, et al
    Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case-control study.
    Headache. 2025 Jul 15. doi: 10.1111/head.15021.
    PubMed     Abstract available
    
    
    
89. ROSEN N, Jenkins A, Hygge Blakeman K, Dai F, et al
    Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States.
    Headache. 2025 Jul 12. doi: 10.1111/head.15004.
    PubMed     Abstract available
    
    
    
90. SMIRNOFF L, Moskatel L, Shaw B, He Z, et al
    A retrospective cohort study to evaluate the effectiveness and safety profile of occipital nerve blocks in the treatment of migraine during pregnancy.
    Headache. 2025 Jul 7. doi: 10.1111/head.15001.
    PubMed     Abstract available
    
    
    
91. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo S
    Letter to the Editor regarding "Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine".
    Headache. 2025;65:1060-1061.
    PubMed    
    
    
    
92. DE DIOS A, Pages-Puigdemont N, Ojeda S, Riera P, et al
    Response to the Letter to the Editor regarding "Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine".
    Headache. 2025;65:1062-1063.
    PubMed    
    
    
    
93. TASMA Z, Siow A, Harris PWR, Brimble MA, et al
    Development and pharmacological characterization of novel multi- calcitonin gene-related peptide and pituitary adenylate cyclase-activating peptide receptor antagonists.
    Headache. 2025;65:1064-1079.
    PubMed     Abstract available
    
    
    June 2025
94. TERWINDT G, Ailani J, Cirillo J, Abraham L, et al
    Underdiagnosis and impact of menstrual migraine in real-world clinical practice: A real-world survey.
    Headache. 2025 Jun 30. doi: 10.1111/head.14996.
    PubMed     Abstract available
    
    
    
95. IKEDA K, Matsumori Y, Kudo M, Ishikawa T, et al
    Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial.
    Headache. 2025 Jun 30. doi: 10.1111/head.14994.
    PubMed     Abstract available
    
    
    
96. KUDROW D, Croop RS, Thiry A, Lipton RB, et al
    A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.
    Headache. 2025 Jun 30. doi: 10.1111/head.15002.
    PubMed     Abstract available
    
    
    
97. MURPHY C, Ladak A, Szperka CL, De Prado BM, et al
    Response to: Reassessing pediatric migraine disability: Toward an updated assessment tool in the era of novel therapeutics.
    Headache. 2025 Jun 24. doi: 10.1111/head.14998.
    PubMed    
    
    
    
98. TAVASOLI AR, Hastriter EV, Little RD, Karnik KT, et al
    Reassessing pediatric migraine disability: Toward an updated assessment tool in the era of novel therapeutics.
    Headache. 2025 Jun 24. doi: 10.1111/head.14969.
    PubMed    
    
    
    
99. LIPTON RB, Gandhi P, Myers K, Bussberg C, et al
    Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete-choice experiment.
    Headache. 2025 Jun 24. doi: 10.1111/head.14974.
    PubMed     Abstract available
    
    
    
100. PELES I, Shneyour RS, Levanon E, Steen YM, et al
     Cardiovascular risk and triptan usage among patients with migraine.
     Headache. 2025 Jun 22. doi: 10.1111/head.14968.
     PubMed     Abstract available
     
     
     
101. KITAMURA S, Matsumori Y, Yamamoto T, Ishikawa T, et al
     Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
     Headache. 2025 Jun 20. doi: 10.1111/head.14995.
     PubMed     Abstract available
     
     
     
102. AHMAD SR, Levin M
     Prevalence of adverse childhood experiences in the refractory chronic migraine population compared to non-refractory chronic and episodic migraine.
     Headache. 2025 Jun 20. doi: 10.1111/head.14986.
     PubMed     Abstract available
     
     
     
103. MONTEITH TS, Lazaridou A, Bernstein C
     Combination behavioral and pharmacological interventions through telehealth platforms: Opportunities for increasing access and optimizing migraine outcomes.
     Headache. 2025 Jun 19. doi: 10.1111/head.14993.
     PubMed    
     
     
     
104. BIRINGER RG
     Regulation of Na(+), K(+)-ATPase by cardiotonic steroids: Participation in the sodium theory for migraine.
     Headache. 2025 Jun 18. doi: 10.1111/head.14980.
     PubMed     Abstract available
     
     
     
105. FOX J, Gaul C, Kuhlencord M, Peperkorn N, et al
     Identifying cognitive-affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions.
     Headache. 2025 Jun 17. doi: 10.1111/head.14988.
     PubMed     Abstract available
     
     
     
106. BRACA S, Russo CV, Stornaiuolo A, Cretella G, et al
     Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study.
     Headache. 2025 Jun 17. doi: 10.1111/head.14991.
     PubMed     Abstract available
     
     
     
107. LIAO CC, Lee CI, Huang YC, Liao KR, et al
     Causal associations between genetically predicted placental weight and migraine.
     Headache. 2025 Jun 11. doi: 10.1111/head.14977.
     PubMed     Abstract available
     
     
     
108. COHEN F, Brooks CV, Sun D, Buse DC, et al
     What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United States.
     Headache. 2025 Jun 5. doi: 10.1111/head.14984.
     PubMed    
     
     
     
109. GETZ M, Charleston L 4th, Armand CE, Willis AW, et al
     Perceived discrimination and migraine-specific quality of life: A cross-sectional survey study in a Black/African American sample.
     Headache. 2025 Jun 2. doi: 10.1111/head.14970.
     PubMed     Abstract available
     
     
     
110. ORAK SA, Polat M, Pak M, Cerci Kubur C, et al
     Can serum neuropeptide levels help diagnose pediatric migraine? A prospective case-control study.
     Headache. 2025 Jun 2. doi: 10.1111/head.14981.
     PubMed     Abstract available
     
     
     
111. GOLDSTEIN H, Rau LM, Humberg C, Bachhausen V, et al
     Efficacy of an educational website on headaches in schoolchildren: A cluster-randomized controlled trial.
     Headache. 2025;65:961-972.
     PubMed     Abstract available
     
     
     May 2025
112. HERSHEY AD, Areberg J, Boserup LP, Lindsten A, et al
     Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine.
     Headache. 2025 May 30. doi: 10.1111/head.14959.
     PubMed     Abstract available
     
     
     
113. NIKITINA V, Santi Laurini G, Montanaro N, Motola D, et al
     Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab.
     Headache. 2025 May 29. doi: 10.1111/head.14962.
     PubMed     Abstract available
     
     
     
114. SEBROW L, Lipton RB, Metts CL, Mattis PJ, et al
     Cognition during ictal and interictal migraine phases: A pilot study using ecological momentary assessment.
     Headache. 2025 May 20. doi: 10.1111/head.14964.
     PubMed     Abstract available
     
     
     
115. YOUSAF MIK, Hussey FD, Pavitt S, Irwin S, et al
     Memantine as a migraine prophylactic agent in adolescents: A retrospective analysis.
     Headache. 2025 May 20. doi: 10.1111/head.14979.
     PubMed    
     
     
     
116. JENSEN MKN, O'Connell ME, Mickleborough MJS
     Perceptions of health, cognition, and pain among middle-aged and older adults with migraine: A population-based cross-sectional study examining findings from the Canadian Longitudinal Study on Aging.
     Headache. 2025 May 20. doi: 10.1111/head.14953.
     PubMed     Abstract available
     
     
     
117. BERMAN G, Mullin K, Smith T, Mosher L, et al
     Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study.
     Headache. 2025 May 20. doi: 10.1111/head.14954.
     PubMed     Abstract available
     
     
     
118. FERRAO MALHEIRO S, Dourado Sotero F, Pereira MB, Nunes Vicente B, et al
     Validation of a Portuguese version of the four-item Migraine Interictal Burden Scale.
     Headache. 2025 May 20. doi: 10.1111/head.14958.
     PubMed     Abstract available
     
     
     
119. MEYDANAL YE, Senisik S, Sirin H
     The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study.
     Headache. 2025 May 20. doi: 10.1111/head.14951.
     PubMed     Abstract available
     
     
     
120. KUCZYNSKI AM, Kingston WS
     Genetic migraine disorders and the response to calcitonin gene-related peptide antagonist treatment.
     Headache. 2025 May 8. doi: 10.1111/head.14942.
     PubMed     Abstract available
     
     
     
121. PLANCHUELO-GOMEZ A, Martin-Martin C, Guerrero AL, Garcia-Azorin D, et al
     Long-term evolution of white and gray matter structural properties in migraine.
     Headache. 2025 May 8. doi: 10.1111/head.14949.
     PubMed     Abstract available
     
     
     
122. TURKEL NN, Vuralli D, Bolay Belen H, Kuruoglu A, et al
     The association of migraine and autistic traits effects on anxiety, depression, and headache-related disability.
     Headache. 2025 May 5. doi: 10.1111/head.14945.
     PubMed     Abstract available
     
     
     
123. DENG MG, Zhou X, Liu F, Wang K, et al
     Plain Language Summary Publication: Investigating the causal and genetic relationship between migraine and Parkinson's disease.
     Headache. 2025 May 5. doi: 10.1111/head.14947.
     PubMed    
     
     
     April 2025
124. GANTENBEIN AR, Kamm CP, Schankin CJ, Zecca C, et al
     Swiss Quality of Life and Health Care Impact Assessment in a Real-World Erenumab-Treated Migraine Population: Results over 2 years.
     Headache. 2025 Apr 30. doi: 10.1111/head.14943.
     PubMed     Abstract available
     
     
     
125. HOUGAARD A
     Time to reconsider the association between migraine and white matter hyperintensities?
     Headache. 2025 Apr 16. doi: 10.1111/head.14940.
     PubMed    
     
     
     
126. SHIRANE R, Cohen F
     Counting the cost: How migraine shapes lives and economies.
     Headache. 2025 Apr 11. doi: 10.1111/head.14941.
     PubMed    
     
     
     
127. NIU PP, Zhang R, Zhang C, Li S, et al
     Association between migraine and cerebral white matter hyperintensities in middle-aged and older individuals: A cross-sectional study using the UK Biobank cohort.
     Headache. 2025 Apr 11. doi: 10.1111/head.14936.
     PubMed     Abstract available
     
     
     
128. REIDY BL, Powers SW, King CD, Kabbouche M, et al
     Youth with high-frequency headaches due to migraine are more vulnerable to non-cephalic pain complaints.
     Headache. 2025;65:655-657.
     PubMed    
     
     
     
129. DE OLIVEIRA AB, Peres MFP, Mercante JPP, Brunoni AR, et al
     Associations of comorbid headache disorders and depression with leisure-time physical activity among 14,088 adults in The Brazilian Longitudinal Study of Adult Health.
     Headache. 2025;65:643-654.
     PubMed     Abstract available
     
     
     March 2025
130. LEWIS JC, Orlova Y, Tietjen GE, Chiang CC, et al
     Migraine and spontaneous coronary artery dissection: A retrospective case-control study.
     Headache. 2025 Mar 28. doi: 10.1111/head.14935.
     PubMed     Abstract available
     
     
     
131. RIMMELE F, Teuber J, Muller B, Giesen S, et al
     Afterimage duration differs for migraine with or without aura.
     Headache. 2025 Mar 28. doi: 10.1111/head.14934.
     PubMed     Abstract available
     
     
     
132. LOPEZ-BRAVO A, Minguez-Olaondo A, Nieves-Castellanos C, Ruibal-Salgado M, et al
     Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study.
     Headache. 2025 Mar 26. doi: 10.1111/head.14913.
     PubMed     Abstract available
     
     
     
133. NAIK VV, Uniyal R, Garg RK, Verma R, et al
     Impact of perilesional edema on severity of migraine in patients with calcified neurocysticercosis: A prospective evaluation.
     Headache. 2025 Mar 24. doi: 10.1111/head.14929.
     PubMed     Abstract available
     
     
     
134. VGONTZAS A, Mittleman MA, Castro-Diehl C, Isasi CR, et al
     Migraine and sleep apnea, insomnia, and sleep patterns in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
     Headache. 2025 Mar 19. doi: 10.1111/head.14926.
     PubMed     Abstract available
     
     
     
135. CHARLES AC, Goadsby PJ
     The cortical spreading depression/migraine aura hypothesis - Finally some definitive evidence.
     Headache. 2025 Mar 19. doi: 10.1111/head.14932.
     PubMed    
     
     
     
136. BUSE DC, Muenzel EJ, Zagar AJ, Mehrabadi AS, et al
     Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study.
     Headache. 2025 Mar 14. doi: 10.1111/head.14925.
     PubMed     Abstract available
     
     
     
137. MAKITA LM, de Kleimmann RF, de Oliveira RR, Neves HAF, et al
     Assessing blood pressure changes and hypertension-related outcomes in patients with migraine treated with erenumab: A systematic review and meta-analysis.
     Headache. 2025 Mar 14. doi: 10.1111/head.14921.
     PubMed     Abstract available
     
     
     
138. SUAREZ-BARCENA PD, Parra-Perez AM, Martin-Lagos J, Gallego-Martinez A, et al
     Machine learning models and classification algorithms in the diagnosis of vestibular migraine: A systematic review and meta-analysis.
     Headache. 2025 Mar 13. doi: 10.1111/head.14924.
     PubMed     Abstract available
     
     
     
139. MCLEOD GA, Josephson CB, Engbers JDT, Cooke LJ, et al
     Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura.
     Headache. 2025 Mar 8. doi: 10.1111/head.14907.
     PubMed     Abstract available
     
     
     
140. OURO A, Castro-Mosquera M, Rodriguez-Arrizabalaga M, Debasa-Mouce M, et al
     Serum levels of autotaxin reveal its role as a novel biomarker of migraine.
     Headache. 2025 Mar 4. doi: 10.1111/head.14922.
     PubMed     Abstract available
     
     
     
141. DODICK DW, Tepper SJ, Ailani J, Khodavirdi AC, et al
     Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort study.
     Headache. 2025 Mar 3. doi: 10.1111/head.14912.
     PubMed     Abstract available
     
     
     
142. LIPTON RB, Kollins JA, Albrecht D
     Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea-A narrative review.
     Headache. 2025;65:527-535.
     PubMed     Abstract available
     
     
     February 2025
143. DE SANTIS F, Foschi M, Romoli M, Mastrangelo V, et al
     Do antithrombotic drugs have a role in migraine prevention? A systematic review.
     Headache. 2025 Feb 24. doi: 10.1111/head.14917.
     PubMed     Abstract available
     
     
     
144. TREADWELL JR, Tsou AY, Rouse B, Ivlev I, et al
     Behavioral interventions for migraine prevention: A systematic review and meta-analysis.
     Headache. 2025 Feb 19. doi: 10.1111/head.14914.
     PubMed     Abstract available
     
     
     
145. JEONG E, Mogos MF, Chen Y
     Association of migraine treatments with reduced ischemic stroke risk: Evidence from two large-scale real-world data analyses.
     Headache. 2025 Feb 14. doi: 10.1111/head.14918.
     PubMed     Abstract available
     
     
     
146. YEH JT, Wang YF, Tzeng YS, Chen SP, et al
     Exploring the impact of acute SARS-CoV-2 infection on headache pattern in patients with migraine: A novel Bayesian analysis.
     Headache. 2025 Feb 10. doi: 10.1111/head.14911.
     PubMed     Abstract available
     
     
     
147. CHEN TY, Hsieh TY, Wang YH, Chang R, et al
     Association between obstructive sleep apnea and migraine: A United States population-based cohort study.
     Headache. 2025 Feb 10. doi: 10.1111/head.14904.
     PubMed     Abstract available
     
     
     
148. SMIRNOFF L, Moskatel LS
     Dyspareunia and pelvic pain in women with chronic migraine: A retrospective, observational analysis.
     Headache. 2025 Feb 4. doi: 10.1111/head.14905.
     PubMed     Abstract available
     
     
     
149. ROMOZZI M, Munafo A, Burgalassi A, De Cesaris F, et al
     Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review.
     Headache. 2025;65:342-352.
     PubMed     Abstract available
     
     
     
150. MANGOLD KI, Katta T, Do V, Moore RD, et al
     White matter hyperintensities and headache in United States military veterans with mild traumatic brain injury.
     Headache. 2025;65:206-215.
     PubMed     Abstract available
     
     
     January 2025
151. KUAN AS, Wang YF, Chen SP, Chuang YF, et al
     Sex differences in pain, suicidal ideation, and suicide attempts in patients with migraine.
     Headache. 2025 Jan 24. doi: 10.1111/head.14906.
     PubMed     Abstract available
     
     
     
152. SENG EK, Muenzel EJ, Shapiro RE, Buse DC, et al
     Development of the Migraine-Related Stigma (MiRS) Questionnaire: Results of the OVERCOME (US) Study.
     Headache. 2025 Jan 22. doi: 10.1111/head.14886.
     PubMed     Abstract available
     
     
     
153. SILVESTRI G, Roccatagliata L, Tazza F, Schiavi S, et al
     The "central vein sign" to differentiate multiple sclerosis from migraine.
     Headache. 2025 Jan 20. doi: 10.1111/head.14902.
     PubMed     Abstract available
     
     
     
154. HARO M, Garate G, Hernandez JL, Olmos JM, et al
     Low serum 25-hydroxyvitamin D levels in migraine are not related to headache frequency: A case-control study in patients with high-frequency/chronic migraine.
     Headache. 2025 Jan 13. doi: 10.1111/head.14901.
     PubMed     Abstract available
     
     
     
155. MINEN MT, Whetten C, Messier D, Mehta S, et al
     Headache diagnosis and treatment: A pilot knowledge and needs assessment among physical therapists.
     Headache. 2025;65:90-100.
     PubMed     Abstract available
     
     
     
156. RIVA E, Kurtis MM, Valls A, Franch O, et al
     Beyond movement: Headache in patients with functional movement disorders.
     Headache. 2025;65:197-201.
     PubMed     Abstract available
     
     
     December 2024
157. BLASZCZYK B, Waliszewska-Prosol M, Smardz J, Wieckiewicz M, et al
     Exploring the associations of sleep bruxism and obstructive sleep apnea with migraine among patients with temporomandibular disorder: A polysomnographic study.
     Headache. 2024 Dec 30. doi: 10.1111/head.14892.
     PubMed     Abstract available
     
     
     
158. YAN L, Huang Y, Xie B, Liu Z, et al
     Association of periodontitis and periodontal parameters with migraine and mortality in people with migraine disease: A nationally representative observational study.
     Headache. 2024 Dec 30. doi: 10.1111/head.14893.
     PubMed     Abstract available
     
     
     
159. OLSON PA, Powers SW
     Behavior and migraine virtual issue.
     Headache. 2024 Dec 30. doi: 10.1111/head.14896.
     PubMed    
     
     
     
160. SHARIFI A, Kouhi A, Steenerson KK, Sharon JD, et al
     Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI) : A narrative review.
     Headache. 2024 Dec 30. doi: 10.1111/head.14866.
     PubMed     Abstract available
     
     
     
161. JAIMES A, Gomez A, Pajares O, Rodriguez-Vico J, et al
     Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study.
     Headache. 2024 Dec 27. doi: 10.1111/head.14865.
     PubMed     Abstract available
     
     
     
162. SU TH, Wang JK, Kuo PH, Chang SH, et al
     The pathogenic role of calcitonin gene-related peptide and predictors of new-onset migraine and long-term outcomes after transcatheter atrial septal defect closure.
     Headache. 2024 Dec 11. doi: 10.1111/head.14885.
     PubMed     Abstract available
     
     
     
163. DENG MG, Zhou X, Liu F, Wang K, et al
     Investigating the causal and genetic relationship between migraine and Parkinson's disease.
     Headache. 2024 Dec 10. doi: 10.1111/head.14881.
     PubMed     Abstract available
     
     
     November 2024
164. HUSSEIN M, Hassan A, Nada MAF, Mohammed Z, et al
     Validity, reliability, and sensitivity to change of the Arabic version of the Migraine-Specific Quality-of-Life Questionnaire after prophylactic treatment.
     Headache. 2024 Nov 27. doi: 10.1111/head.14874.
     PubMed     Abstract available
     
     
     
165. PANZA GA, Johnson MAL, Kuruvilla DE
     A post hoc analysis of migraine-associated symptoms from the phase 3 randomized, double-blind, sham-controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (TEAM) study.
     Headache. 2024 Nov 27. doi: 10.1111/head.14860.
     PubMed     Abstract available
     
     
     
166. LIPTON RB, Gendolla A, Abraham L, Jenkins A, et al
     Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review.
     Headache. 2024 Nov 27. doi: 10.1111/head.14854.
     PubMed     Abstract available
     
     
     
167. AILANI J, Lipton RB, Blumenfeld AM, Mechtler L, et al
     Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.
     Headache. 2024 Nov 21. doi: 10.1111/head.14871.
     PubMed     Abstract available
     
     
     
168. GOPALAKRISHNAN R, Malan NS, Mandava N, Dunn EJ, et al
     Magnetoencephalography studies in migraine and headache disorders: A systematic review.
     Headache. 2024 Nov 10. doi: 10.1111/head.14867.
     PubMed     Abstract available
     
     
     
169. DAGHLAS I, Rist PM, Chasman DI
     Genetically proxied liability to migraine and risk of intracranial aneurysm and subarachnoid hemorrhage.
     Headache. 2024 Nov 7. doi: 10.1111/head.14851.
     PubMed     Abstract available
     
     
     
170. BERTZ RJ, Collins JL, Madonia J, Bhardwaj R, et al
     Comparative bioavailability of single-dose zavegepant during and between migraine attacks: A phase 1, randomized, open-label, fixed-sequence, two-period study.
     Headache. 2024 Nov 7. doi: 10.1111/head.14856.
     PubMed     Abstract available
     
     
     
171. GRYGLAS-DWORAK A, Schim J, Ettrup A, Boserup LP, et al
     Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.
     Headache. 2024 Nov 5. doi: 10.1111/head.14862.
     PubMed     Abstract available
     
     
     
172. SHEWALE AR, Poh W, Reed ML, Liu J, et al
     Ubrogepant users' real-world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study.
     Headache. 2024;64:1244-1252.
     PubMed     Abstract available
     
     
     
173. CASCELLA RH, Anderson CC, Perez EJ
     The impact of updates in headache quality measures on adherence to best practices in a neurology resident clinic: A quality improvement study.
     Headache. 2024;64:1329-1335.
     PubMed     Abstract available
     
     
     October 2024
174. PATTERSON GENTILE C, Szperka CL, Hershey AD
     Cluster Analysis of Migraine-associated Symptoms (CAMS) in youth: A retrospective cross-sectional multicenter study.
     Headache. 2024 Oct 27. doi: 10.1111/head.14859.
     PubMed     Abstract available
     
     
     
175. PATTERSON GENTILE C, Hershey AD, Szperka CL
     A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross-sectional headache registry study in youth.
     Headache. 2024 Oct 27. doi: 10.1111/head.14858.
     PubMed     Abstract available
     
     
     
176. COHEN F, Brooks CV, Sun D, Buse DC, et al
     Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findings.
     Headache. 2024 Oct 23. doi: 10.1111/head.14864.
     PubMed    
     
     
     
177. TAVASOLI AR, Rastogi RG, Hastriter EV
     Rising migraine incidence in adolescents despite stable prevalence in the US: A call for further investigation.
     Headache. 2024 Oct 19. doi: 10.1111/head.14844.
     PubMed    
     
     
     
178. SENG EK, Hill J, Reeder AK, Visvanathan P, et al
     Feasibility, acceptability, and fidelity of remote-delivered abbreviated mindfulness-based cognitive therapy interventions for patients with migraine and depressive symptoms.
     Headache. 2024 Oct 14. doi: 10.1111/head.14857.
     PubMed     Abstract available
     
     
     
179. RUIZ-TAGLE A, Caetano G, Fouto A, Esteves I, et al
     Preserved working memory performance along with subcortical modulation during peri-ictal phases in spontaneous migraine attacks.
     Headache. 2024 Oct 13. doi: 10.1111/head.14850.
     PubMed     Abstract available
     
     
     
180. KIRKLAND S, Meyer J, Visser L, Campbell S, et al
     The effectiveness of parenteral agents to mitigate relapses after severe acute migraine headache presentations: A systematic review and network analysis.
     Headache. 2024 Oct 4. doi: 10.1111/head.14841.
     PubMed     Abstract available
     
     
     
181. BHARDWAJ R, Donohue MK, Madonia J, Matschke K, et al
     Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo-controlled study in healthy adults.
     Headache. 2024 Oct 4. doi: 10.1111/head.14853.
     PubMed     Abstract available
     
     
     
182. TUMMOSZEIT IZ, Olofsson IA, Chalmer MA, Henriksen AP, et al
     No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study.
     Headache. 2024 Oct 1. doi: 10.1111/head.14784.
     PubMed     Abstract available
     
     
     September 2024
183. SOTTANI C, Di Lazzaro G, Calabresi P, Pomponi MG, et al
     Efficacy of galcanezumab in proline-rich transmembrane protein 2 (PRRT2)-associated familial hemiplegic migraine: A case series.
     Headache. 2024 Sep 30. doi: 10.1111/head.14840.
     PubMed     Abstract available
     
     
     
184. SHARON JD, Krauter R, Chae R, Gardi A, et al
     A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study.
     Headache. 2024 Sep 30. doi: 10.1111/head.14835.
     PubMed     Abstract available
     
     
     
185. PEASAH SK, Soh YH, Huang Y, Nguyen J, et al
     Patient reported outcomes and the real-world use of calcitonin gene-related peptide medications in migraine.
     Headache. 2024 Sep 30. doi: 10.1111/head.14843.
     PubMed     Abstract available
     
     
     
186. ORR SL, Kuziek J, Ali S, Anderson E, et al
     Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double-dummy pilot trial.
     Headache. 2024 Sep 17. doi: 10.1111/head.14838.
     PubMed     Abstract available
     
     
     
187. SOTERO FD, Nobre J, Vicente BN, Martins IP, et al
     Predictors of migraine interictal burden: The hidden role of subjective memory complaints.
     Headache. 2024 Sep 13. doi: 10.1111/head.14819.
     PubMed     Abstract available
     
     
     
188. KANG S, Eun Y, Han K, Jung J, et al
     Heightened migraine risk in patients with rheumatoid arthritis: A national retrospective cohort study.
     Headache. 2024 Sep 13. doi: 10.1111/head.14832.
     PubMed     Abstract available
     
     
     
189. DE DIOS A, Pages-Puigdemont N, Ojeda S, Riera P, et al
     Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine.
     Headache. 2024 Sep 13. doi: 10.1111/head.14827.
     PubMed     Abstract available
     
     
     
190. MULTANI JK, Urman R, Park AS, Gill K, et al
     Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study.
     Headache. 2024 Sep 9. doi: 10.1111/head.14820.
     PubMed     Abstract available
     
     
     
191. AILANI J, Gandhi P, Lalla A, Halker Singh R, et al
     Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine.
     Headache. 2024 Sep 9. doi: 10.1111/head.14824.
     PubMed     Abstract available
     
     
     
192. MCGINLEY JS, Mangrum R, Gerstein MT, McCarrier KP, et al
     Symptoms across the phases of the migraine cycle from the patient's perspective: Results of the MiCOAS qualitative study.
     Headache. 2024 Sep 2. doi: 10.1111/head.14817.
     PubMed     Abstract available
     
     
     
193. TATSUMOTO M, Ishida M, Iba K, Kim BK, et al
     Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial.
     Headache. 2024 Sep 2. doi: 10.1111/head.14810.
     PubMed     Abstract available
     
     
     
194. MOHAMMADNEZHAD G, Assarzadegan F, Koosha M, Esmaily H, et al
     Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial.
     Headache. 2024 Sep 2. doi: 10.1111/head.14808.
     PubMed     Abstract available
     
     
     
195. MARTIN EG, Kuziek J, Rasiah J, Orr SL, et al
     Evaluating patient and family preferences for acute and preventive pediatric headache treatment.
     Headache. 2024;64:950-966.
     PubMed     Abstract available
     
     
     August 2024
196. SMITH DC, Zhang J, Jayasuriya S, Berisha V, et al
     The impact of headache intensity on speech in participants with migraine and acute post-traumatic headache.
     Headache. 2024 Aug 28. doi: 10.1111/head.14809.
     PubMed     Abstract available
     
     
     
197. FUGLSANG CH, Pedersen L, Schmidt M, Vandenbroucke JP, et al
     The combined impact of migraine and gestational diabetes on long-term risk of premature myocardial infarction and stroke: A population-based cohort study.
     Headache. 2024 Aug 28. doi: 10.1111/head.14821.
     PubMed     Abstract available
     
     
     
198. KIM JR, Park TJ, Agapova M, Blumenfeld A, et al
     Healthcare resource use and costs associated with the misdiagnosis of migraine.
     Headache. 2024 Aug 28. doi: 10.1111/head.14822.
     PubMed     Abstract available
     
     
     
199. HERBERT MS, Merritt VC, Afari N, Gasperi M, et al
     Cognitive symptoms in veterans with migraine or traumatic brain injury: A Million Veteran Program study.
     Headache. 2024 Aug 28. doi: 10.1111/head.14815.
     PubMed     Abstract available
     
     
     
200. DENNEY DE, Lee AA, Landy SH, Smitherman TA, et al
     Plain language summary publication: Headache-related disability as a function of migraine aura: A daily diary study.
     Headache. 2024 Aug 23. doi: 10.1111/head.14811.
     PubMed    
     
     
     
201. CHIANG CC, Schwedt TJ, Dumkrieger G, Wang L, et al
     Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features.
     Headache. 2024 Aug 23. doi: 10.1111/head.14806.
     PubMed     Abstract available
     
     
     
202. SHARMA TL, Lucas S, Barber J, Hoffman JM, et al
     Pilot study evaluating treatment with sumatriptan for moderate to severe post-traumatic headache: A phase 2 open-label study.
     Headache. 2024 Aug 13. doi: 10.1111/head.14807.
     PubMed     Abstract available
     
     
     
203. LINDSAY R, Kalifa A, Kuziek J, Kabbouche M, et al
     The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta-analysis.
     Headache. 2024 Aug 11. doi: 10.1111/head.14798.
     PubMed     Abstract available
     
     
     
204. DENNEY DE, Lee AA, Landy SH, Smitherman TA, et al
     Headache-related disability as a function of migraine aura: A daily diary study.
     Headache. 2024 Aug 1. doi: 10.1111/head.14796.
     PubMed     Abstract available
     
     
     
205. SUZUKI Y, Kiyosawa M, Wakakura M, Ishii K, et al
     Plain Language Summary Publication: Hyperactivity of the medial thalamus in patients with photophobia-associated migraine.
     Headache. 2024 Aug 1. doi: 10.1111/head.14792.
     PubMed    
     
     
     July 2024
206. DUMKRIEGER GM, Ishii R, Goadsby PJ
     Flexible modeling of headache frequency fluctuations in migraine with hidden Markov models.
     Headache. 2024 Jul 30. doi: 10.1111/head.14782.
     PubMed     Abstract available
     
     
     
207. TRIVEDI M, Dumkrieger G, Chong CD, Leibovit-Reiben Z, et al
     A history of abuse is associated with more severe migraine- and pain-related disability: Results from the American Registry for Migraine Research.
     Headache. 2024 Jul 25. doi: 10.1111/head.14787.
     PubMed     Abstract available
     
     
     
208. SUZUKI Y, Kiyosawa M, Wakakura M, Ishii K, et al
     Hyperactivity of the medial thalamus in patients with photophobia-associated migraine.
     Headache. 2024 Jul 18. doi: 10.1111/head.14785.
     PubMed     Abstract available
     
     
     
209. BURNS KN, Zhao H, Master C, Langford D, et al
     Migraine epidemiology in collegiate student-athletes: Findings from the Concussion Assessment, Research, and Education (CARE) Consortium.
     Headache. 2024 Jul 18. doi: 10.1111/head.14799.
     PubMed     Abstract available
     
     
     
210. OLOFSSON IA
     Migraine heritability and beyond: A scoping review of twin studies.
     Headache. 2024 Jul 18. doi: 10.1111/head.14789.
     PubMed     Abstract available
     
     
     
211. CHARLESTON L 4TH
     Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Association: A pilot project.
     Headache. 2024 Jul 16. doi: 10.1111/head.14791.
     PubMed     Abstract available
     
     
     
212. ORNELLO R, Baldini F, Onofri A, Rosignoli C, et al
     Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-A real-world study.
     Headache. 2024 Jul 16. doi: 10.1111/head.14788.
     PubMed     Abstract available
     
     
     
213. MATHARU M, Katsarava Z, Buse DC, Sommer K, et al
     Plain Language Summary Publication: Characterizing neck pain during headache among people with migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) cross-sectional study.
     Headache. 2024 Jul 16. doi: 10.1111/head.14786.
     PubMed    
     
     
     
214. BOUGIE JK, Krupsky K, Beusterien K, Ladouceur MP, et al
     Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment.
     Headache. 2024 Jul 9. doi: 10.1111/head.14781.
     PubMed     Abstract available
     
     
     
215. LIPTON RB, Ailani J, Mullin K, Pavlovic JM, et al
     Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
     Headache. 2024 Jul 3. doi: 10.1111/head.14775.
     PubMed     Abstract available
     
     
     
216. ROBBLEE J, Orlova YY, Ahn AH, Ali AS, et al
     Real-world approaches to outpatient treatment of status migrainosus: A survey study.
     Headache. 2024 Jul 3. doi: 10.1111/head.14769.
     PubMed     Abstract available
     
     
     
217. SILBERSTEIN SD, Diener HC, Dodick DW, Sommer K, et al
     Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
     Headache. 2024;64:838-848.
     PubMed     Abstract available
     
     
     
218. MATHARU M, Katsarava Z, Buse DC, Sommer K, et al
     Characterizing neck pain during headache among people with migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) cross-sectional study.
     Headache. 2024;64:750-763.
     PubMed     Abstract available
     
     
     
219. ROBBLEE J, Zhao XR, Minen MT, Friedman BW, et al
     Plain Language Summary Publication: The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American headache society evidence assessment of parenteral pharmacotherapies.
     Headache. 2024;64:901-902.
     PubMed    
     
     
     
220. KLAN T, Brascher AK, Seng EK, Gaul C, et al
     German language adaptation of the Cogniphobia Scale for Headache Disorders (CS-HD) and development of a new short form (CS-HD-6).
     Headache. 2024;64:772-782.
     PubMed     Abstract available
     
     
     June 2024
221. ORR SL
     Parental mental health and migraine in youth: An evolving story historically plagued with sparse and inadequate literature and mother-blaming.
     Headache. 2024 Jun 27. doi: 10.1111/head.14779.
     PubMed    
     
     
     
222. MARZOUK MA, Buse DC, Karvounides D, Powers SW, et al
     Not their fault: Mental health characteristics of parents with migraine and the migraine status of their children.
     Headache. 2024 Jun 27. doi: 10.1111/head.14773.
     PubMed    
     
     
     
223. VURAL S, Turksoy VA, Uzun Akgeyik A, Kusdogan M, et al
     Heavy metal and trace element alterations in patients during a migraine attack.
     Headache. 2024 Jun 27. doi: 10.1111/head.14748.
     PubMed     Abstract available
     
     
     
224. VIVES-MESTRES M, Casanova A, Silberstein SD, Hershey AD, et al
     Clinical factors associated with day-to-day peak pain severity in individuals with chronic migraine: A cohort study using daily prospective diary data.
     Headache. 2024 Jun 27. doi: 10.1111/head.14745.
     PubMed     Abstract available
     
     
     
225. BLUMENFELD A, Kudrow D, McAllister P, Boserup LP, et al
     Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache.
     Headache. 2024 Jun 24. doi: 10.1111/head.14767.
     PubMed     Abstract available
     
     
     
226. PASCUAL-MATO M, Garate G, Gonzalez-Quintanilla V, Madera-Fernandez J, et al
     Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study.
     Headache. 2024 Jun 24. doi: 10.1111/head.14768.
     PubMed     Abstract available
     
     
     
227. CROPPER HC, Conway CM, Wyche W, Pradhan AA, et al
     Glial activation in pain and emotional processing regions in the nitroglycerin mouse model of chronic migraine.
     Headache. 2024 Jun 20. doi: 10.1111/head.14740.
     PubMed     Abstract available
     
     
     
228. JOSHI S, Spargo A, Hoyt M, Panni T, et al
     A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
     Headache. 2024 Jun 19. doi: 10.1111/head.14741.
     PubMed     Abstract available
     
     
     
229. NANDYALA A, Burch R, Halker Singh R
     Migraine in women.
     Headache. 2024 Jun 14. doi: 10.1111/head.14783.
     PubMed    
     
     
     
230. WELLS RE, O'Connell N, Minen MT
     Mechanisms for mindfulness in migraine: Does catastrophizing matter?
     Headache. 2024 Jun 6. doi: 10.1111/head.14730.
     PubMed    
     
     
     
231. CONTI M, Bovenzi R, Palmieri MG, Placidi F, et al
     Early effect of onabotulinumtoxinA on EEG-based functional connectivity in patients with chronic migraine: A pilot study.
     Headache. 2024 Jun 4. doi: 10.1111/head.14750.
     PubMed     Abstract available
     
     
     
232. ROBBLEE J, Zhao XR, Minen MT, Friedman BW, et al
     The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
     Headache. 2024 Jun 3. doi: 10.1111/head.14744.
     PubMed     Abstract available
     
     
     May 2024
233. DAFER RM, Tietjen GE, Rothrock JF, Vann RE, et al
     Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
     Headache. 2024 May 27. doi: 10.1111/head.14669.
     PubMed     Abstract available
     
     
     
234. SU Y, Tay VQ, Singh S, Leary MC, et al
     A retrospective review of sex differences of white matter hyperintensities in brain MRI of patients with migraine.
     Headache. 2024 May 24. doi: 10.1111/head.14714.
     PubMed     Abstract available
     
     
     
235. WANG SJ, Kim BK, Wang H, Zhou J, et al
     Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study.
     Headache. 2024 May 24. doi: 10.1111/head.14733.
     PubMed     Abstract available
     
     
     
236. ZHAO YJ, Ong JJY, Sonu SK, Dang J, et al
     A real-world prospective observational study of eptinezumab in Asian patients with migraine.
     Headache. 2024 May 24. doi: 10.1111/head.14737.
     PubMed     Abstract available
     
     
     
237. ASHINA S, Muenzel EJ, Nicholson RA, Zagar AJ, et al
     Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) study.
     Headache. 2024 May 24. doi: 10.1111/head.14729.
     PubMed     Abstract available
     
     
     
238. SHAO SC, Hentz J, Shank P, Leonard M, et al
     Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial.
     Headache. 2024 May 23. doi: 10.1111/head.14732.
     PubMed     Abstract available
     
     
     
239. MAY A
     Beyond aura: Understanding migraine as a cycling pan-sensory threshold disease.
     Headache. 2024 May 23. doi: 10.1111/head.14736.
     PubMed    
     
     
     
240. BUSE DC, Sakai F, Matharu M, Reed ML, et al
     Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi-country results from the CaMEO-I study.
     Headache. 2024 May 5. doi: 10.1111/head.14721.
     PubMed     Abstract available
     
     
     
241. ANDERSON CC, Iser CR, Hirte IL, Boddu S, et al
     Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
     Headache. 2024 May 3. doi: 10.1111/head.14725.
     PubMed     Abstract available
     
     
     
242. COHEN F, Brooks CV, Sun D, Buse DC, et al
     Prevalence and burden of migraine in the United States: A systematic review.
     Headache. 2024 May 3. doi: 10.1111/head.14709.
     PubMed     Abstract available
     
     
     
243. REDUCHA PV, Bomers JP, Edvinsson L, Haanes KA, et al
     The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model.
     Headache. 2024 May 3. doi: 10.1111/head.14726.
     PubMed     Abstract available
     
     
     
244. INCE MS, Guzel I, Akgor MC, Bahcelioglu M, et al
     Virtual dynamic interaction games reveal impaired multisensory integration in women with migraine.
     Headache. 2024 May 1. doi: 10.1111/head.14720.
     PubMed     Abstract available
     
     
     April 2024
245. XU D, Wu B
     Investigating the causal association between systemic lupus erythematosus and migraine using Mendelian randomization analysis.
     Headache. 2024 Apr 28. doi: 10.1111/head.14723.
     PubMed     Abstract available
     
     
     
246. ZHU G, Wang M, Kong F
     Blood serum levels of PACAP and migraine onset: A systematic review and meta-analysis of observational studies.
     Headache. 2024 Apr 24. doi: 10.1111/head.14711.
     PubMed     Abstract available
     
     
     
247. HUSSEIN M, Hassan A, Nada MAF, Mohammed Z, et al
     Reliability, validity, and responsiveness of the Arabic version of HIT-6 questionnaire in patients with migraine indicated for preventive therapy: A multi-center study.
     Headache. 2024 Apr 23. doi: 10.1111/head.14719.
     PubMed     Abstract available
     
     
     
248. ERMAKOVA E, Shaidullova K, Gafurov O, Kabirova A, et al
     Implications of high homocysteine levels in migraine pain: An experimental study of the excitability of peripheral meningeal afferents in rats with hyperhomocysteinemia.
     Headache. 2024 Apr 22. doi: 10.1111/head.14710.
     PubMed     Abstract available
     
     
     
249. VYAS MV, Lee N, Lay C
     Association between migraine and exclusive breastfeeding: A cross-sectional study.
     Headache. 2024 Apr 21. doi: 10.1111/head.14713.
     PubMed     Abstract available
     
     
     
250. GELFAND AA
     Depression and anxiety are not associated with migraine outcomes in children and adolescents.
     Headache. 2024 Apr 18. doi: 10.1111/head.14700.
     PubMed    
     
     
     
251. ROBBLEE J, Hakim SM, Reynolds JM, Monteith TS, et al
     Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
     Headache. 2024 Apr 18. doi: 10.1111/head.14693.
     PubMed     Abstract available
     
     
     
252. REINA-VARONA A, Madronero-Miguel B, Fierro-Marrero J, Paris-Alemany A, et al
     Efficacy of various exercise interventions for migraine treatment: A systematic review and network meta-analysis.
     Headache. 2024 Apr 10. doi: 10.1111/head.14696.
     PubMed     Abstract available
     
     
     
253. RIZVI BA, Kuziek J, Cho LY, Ronksley PE, et al
     Anxiety and depressive symptoms and migraine-related outcomes in children and adolescents.
     Headache. 2024 Apr 6. doi: 10.1111/head.14701.
     PubMed     Abstract available
     
     
     
254. KIRKLAND SW, Visser L, Meyer J, Junqueira DR, et al
     The effectiveness of parenteral agents for pain reduction in patients with migraine presenting to emergency settings: A systematic review and network analysis.
     Headache. 2024;64:424-447.
     PubMed     Abstract available
     
     
     
255. SEEBADRI-WHITE C, Yuan H, Young WB, Arca KN, et al
     Advocacy Connection Team-Now educational program for headache fellows and patients/caregivers: Assessment of educational objectives.
     Headache. 2024;64:374-379.
     PubMed     Abstract available
     
     
     March 2024
256. DODICK DW, Reed ML, Lee L, Balkaran BL, et al
     Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States.
     Headache. 2024 Mar 24. doi: 10.1111/head.14684.
     PubMed     Abstract available
     
     
     
257. KRIKOVA I, Digre KB, Katz BJ, Seay MD, et al
     Migraine, idiopathic intracranial hypertension, and calcitonin gene-related peptide antibodies.
     Headache. 2024 Mar 13. doi: 10.1111/head.14686.
     PubMed    
     
     
     
258. CHARLES AC, Digre KB, Goadsby PJ, Robbins MS, et al
     Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
     Headache. 2024 Mar 11. doi: 10.1111/head.14692.
     PubMed     Abstract available
     
     
     
259. SPROUSE BLUM AS, DaSilva LA, Greenberg MD, Nissenbaum AJ, et al
     Comparison of migraine with left- versus right-sided headache: A cross-sectional study.
     Headache. 2024 Mar 3. doi: 10.1111/head.14689.
     PubMed     Abstract available
     
     
     
260. HOOGEVEEN ES, Pelzer N, Ghariq E, van Osch MJP, et al
     Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual-echo arterial spin labeling MRI study.
     Headache. 2024 Mar 2. doi: 10.1111/head.14680.
     PubMed     Abstract available
     
     
     
261. GIBLER RC, Knestrick KE, Powers SW, Hershey AD, et al
     Preliminary prospective observational investigation of clinical outcomes among treatment-seeking youth with continuous headache.
     Headache. 2024;64:319-322.
     PubMed    
     
     
     
262. LIPTON RB, Albrecht D, Bermudez M, Hu J, et al
     A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
     Headache. 2024;64:266-275.
     PubMed     Abstract available
     
     
     February 2024
263. SCUTELNIC A, Sutter NL, Beyeler M, Meinel TR, et al
     Characteristics of acute ischemic stroke and unusual aura in patients with migraine with aura.
     Headache. 2024 Feb 27. doi: 10.1111/head.14682.
     PubMed     Abstract available
     
     
     
264. CHHABRA N, Mead-Harvey C, Dodoo CA, Iser C, et al
     Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience.
     Headache. 2024 Feb 27. doi: 10.1111/head.14679.
     PubMed     Abstract available
     
     
     
265. 
     Correction to: "Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial".
     Headache. 2024 Feb 26. doi: 10.1111/head.14691.
     PubMed    
     
     
     
266. ROSSIGNOL J, Ouimet T, Poras H, Dallel R, et al
     Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine.
     Headache. 2024 Feb 22. doi: 10.1111/head.14681.
     PubMed     Abstract available
     
     
     
267. MITTLEMAN MR, Mostofsky E, Vgontzas A, Bertisch SM, et al
     Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study.
     Headache. 2024 Feb 6. doi: 10.1111/head.14673.
     PubMed     Abstract available
     
     
     
268. VAN DEN HOEK TC, Verhagen IE, de Boer I, Terwindt GM, et al
     Substance use in a Dutch migraine cohort compared with the general population.
     Headache. 2024 Feb 1. doi: 10.1111/head.14663.
     PubMed     Abstract available
     
     
     
269. LANGDON RL, DiSabella MT, Strelzik JA
     Screen time and pediatric headache: A scoping review of the literature.
     Headache. 2024;64:211-225.
     PubMed     Abstract available
     
     
     
270. HAN C, Lim JY, Koike N, Kim SY, et al
     Regulation of headache response and transcriptomic network by the trigeminal ganglion clock.
     Headache. 2024;64:195-210.
     PubMed     Abstract available
     
     
     
271. JICHA C, Pham K
     Neuromodulation for primary headache disorders: Advantages and challenges.
     Headache. 2024;64:226-228.
     PubMed    
     
     
     
272. PRADHAN SK, Gantenbein AR, Li Y, Shaban H, et al
     Daith piercing: Revisited from the perspective of auricular acupuncture systems. A narrative review.
     Headache. 2024;64:131-140.
     PubMed     Abstract available
     
     
     January 2024
273. ZHANG P, Ventrapragada A, Shapiro RE, Do TP, et al
     Metaphorical use of "headache" and "migraine" in media: A longitudinal study of 1.3 million articles in major publications.
     Headache. 2024 Jan 18. doi: 10.1111/head.14661.
     PubMed     Abstract available
     
     
     
274. VGONTZAS A
     Examining substance use patterns in adults with migraine: A changing landscape.
     Headache. 2024 Jan 18. doi: 10.1111/head.14660.
     PubMed    
     
     
     
275. MANGRUM R, Bryant AL, Gerstein MT, McCarrier KP, et al
     The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.
     Headache. 2024 Jan 18. doi: 10.1111/head.14664.
     PubMed     Abstract available
     
     
     
276. PATNIYOT I, Banerjee A, Nobleza K, Nguyen D, et al
     A retrospective analysis of the use of candesartan for migraine prevention in adolescents.
     Headache. 2024;64:96-97.
     PubMed    
     
     
     
277. DE OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
     Persistent headache attributed to past ischemic stroke: A prospective cohort study.
     Headache. 2024;64:48-54.
     PubMed     Abstract available
     
     
     December 2023
278. BELTRAMONE M, Redon S, Donnet A
     Bone site fracture pain after subcutaneous sumatriptan injection: A report of two cases.
     Headache. 2023 Dec 29. doi: 10.1111/head.14662.
     PubMed    
     
     
     
279. RHUDY C, Schadler A, Huffmyer M, Porter L, et al
     Rural disparities in emergency department utilization for migraine care.
     Headache. 2023 Dec 12. doi: 10.1111/head.14659.
     PubMed     Abstract available
     
     
     
280. CHASE BA, Semenov I, Rubin S, Meyers S, et al
     Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
     Headache. 2023 Dec 10. doi: 10.1111/head.14655.
     PubMed     Abstract available
     
     
     November 2023
281. PODRAZA K, Bangera N, Feliz A, Charles A, et al
     Reduction in retinal microvascular perfusion during migraine attacks.
     Headache. 2023 Nov 30. doi: 10.1111/head.14654.
     PubMed     Abstract available
     
     
     
282. MACGREGOR EA, Okonkwo R, Detke HC, Polavieja P, et al
     Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2.
     Headache. 2023 Nov 28. doi: 10.1111/head.14652.
     PubMed     Abstract available
     
     
     
283. ASHINA M, Mitsikostas DD, Ramirez Campos V, Barash S, et al
     Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
     Headache. 2023 Nov 13. doi: 10.1111/head.14651.
     PubMed     Abstract available
     
     
     
284. WU J, Yang P, Wu X, Yu X, et al
     Association between secondhand smoke exposure and severe headaches or migraine in never-smoking adults.
     Headache. 2023 Nov 8. doi: 10.1111/head.14640.
     PubMed     Abstract available
     
     
     
285. SZPERKA CL, Witzman S, Ostapenko S, Farrar JT, et al
     Patient headache questionnaires can improve headache diagnosis and treatment in children.
     Headache. 2023;63:1359-1371.
     PubMed     Abstract available
     
     
     
286. IACONANGELO CJ, Serrano D, Adams AM, Trugman JM, et al
     Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
     Headache. 2023;63:1412-1422.
     PubMed     Abstract available
     
     
     
287. HYERACI G, Paoletti O, Iannone LF, Gini R, et al
     Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
     Headache. 2023;63:1391-1402.
     PubMed     Abstract available
     
     
     
288. MERLI E, Rustici A, Gramegna LL, Di Donato M, et al
     Vessel-wall MRI in primary headaches: The role of neurogenic inflammation.
     Headache. 2023;63:1372-1379.
     PubMed     Abstract available
     
     
     October 2023
289. MOSKATEL LS, Graber-Naidich A, He Z, Zhang N, et al
     The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
     Headache. 2023 Oct 26. doi: 10.1111/head.14642.
     PubMed     Abstract available
     
     
     
290. CHIANG CC
     Hypermobility spectrum disorders and migraine in adolescents.
     Headache. 2023 Oct 24. doi: 10.1111/head.14650.
     PubMed    
     
     
     
291. PORTT AE, Orchard C, Chen H, Ge E, et al
     Migraine and air pollution: A systematic review.
     Headache. 2023 Oct 5. doi: 10.1111/head.14632.
     PubMed     Abstract available
     
     
     
292. LIPTON RB, Pozo-Rosich P, Orr SL, Reed ML, et al
     Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.
     Headache. 2023 Oct 5. doi: 10.1111/head.14629.
     PubMed     Abstract available
     
     
     
293. MCCRACKEN HT, Lee AA, Smitherman TA
     Headache and psychological variables as predictors of disability in individuals with primary headache disorders.
     Headache. 2023;63:1259-1270.
     PubMed     Abstract available
     
     
     September 2023
294. MD ISA NA, Tummanapalli SS, Chiang JCB, Krishnan AV, et al
     Neuropathic changes in corneal nerve endings-A potential objective biomarker for migraine frequency and response to treatment.
     Headache. 2023 Sep 23. doi: 10.1111/head.14630.
     PubMed    
     
     
     
295. WANG VS, Kosman J, Yuan H, Lauritsen C, et al
     Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study.
     Headache. 2023 Sep 23. doi: 10.1111/head.14636.
     PubMed     Abstract available
     
     
     
296. KRUSE JA, Seng EK
     Changes in cognitive appraisal in a randomized controlled trial of mindfulness-based cognitive therapy for patients with migraine.
     Headache. 2023 Sep 18. doi: 10.1111/head.14627.
     PubMed     Abstract available
     
     
     
297. SHAPIRO HFJ, Loder E, Shapiro DJ
     Association between clinician specialty and prescription of preventive medication for young adults with migraine: A retrospective cohort study.
     Headache. 2023 Sep 11. doi: 10.1111/head.14628.
     PubMed     Abstract available
     
     
     
298. SILVA-NETO RP, Soares AA, Souza WPO, Krymchantowski AG, et al
     "Growing pains" in children and adolescents as an early symptom of migraine: A prospective study.
     Headache. 2023 Sep 6. doi: 10.1111/head.14608.
     PubMed     Abstract available
     
     
     
299. CHARLES A
     Aura is a symptom of a migraine attack, not its cause.
     Headache. 2023 Sep 4. doi: 10.1111/head.14623.
     PubMed    
     
     
     
300. CLEMENTI MA, Kienzler C, Yonker M, Harmon M, et al
     Preliminary exploration of a multidimensional sleep health composite in adolescent females with frequent migraine.
     Headache. 2023 Sep 1. doi: 10.1111/head.14626.
     PubMed     Abstract available
     
     
     
301. LIU H, Zhang S, Gong Z, Zhao W, et al
     Association between migraine and cardiovascular disease mortality: A prospective population-based cohort study.
     Headache. 2023 Sep 1. doi: 10.1111/head.14616.
     PubMed     Abstract available
     
     
     
302. LEI X, Wei M, Wang L, Liu C, et al
     Resting-state electroencephalography microstate dynamics altered in patients with migraine with and without aura-A pilot study.
     Headache. 2023 Sep 1. doi: 10.1111/head.14622.
     PubMed     Abstract available
     
     
     
303. TEPPER SJ, Schwedt TJ, Vo P, Thompson J, et al
     Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
     Headache. 2023 Sep 1. doi: 10.1111/head.14612.
     PubMed     Abstract available
     
     
     
304. MACGREGOR EA, Hutchinson S, Lai H, Dabruzzo B, et al
     Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
     Headache. 2023 Sep 1. doi: 10.1111/head.14619.
     PubMed     Abstract available
     
     
     
305. 
     Correction to "Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labelling".
     Headache. 2023;63:1199.
     PubMed    
     
     
     
306. MARTINDALE C, Presson AP, Schwedt TJ, Brennan KC, et al
     Sensory hypersensitivities are associated with post-traumatic headache-related disability.
     Headache. 2023;63:1061-1069.
     PubMed     Abstract available
     
     
     
307. FILA M, Pawlowska E, Szczepanska J, Blasiak J, et al
     Autophagy may protect the brain against prolonged consequences of headache attacks: A narrative/hypothesis review.
     Headache. 2023;63:1154-1166.
     PubMed     Abstract available
     
     
     
308. KATSUKI M, Matsumori Y, Kawamura S, Kashiwagi K, et al
     Developing an artificial intelligence-based diagnostic model of headaches from a dataset of clinic patients' records.
     Headache. 2023;63:1097-1108.
     PubMed     Abstract available
     
     
     August 2023
309. ZAMIR O, Yarns BC, Lagman-Bartolome AM, Jobanputra L, et al
     Understanding the gaps in headache and migraine treatment with psychological and behavioral interventions: A narrative review.
     Headache. 2023 Aug 28. doi: 10.1111/head.14624.
     PubMed     Abstract available
     
     
     
310. POLK AN, Smitherman TA
     A meta-analytic review of acceptance-based interventions for migraine.
     Headache. 2023 Aug 27. doi: 10.1111/head.14614.
     PubMed     Abstract available
     
     
     
311. RICHER L, Luu H, Martins KJB, Vu K, et al
     Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada.
     Headache. 2023 Aug 23. doi: 10.1111/head.14613.
     PubMed     Abstract available
     
     
     
312. MATSUMORI Y, Ishida M, Iba K, Kim BK, et al
     Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.
     Headache. 2023 Aug 21. doi: 10.1111/head.14606.
     PubMed     Abstract available
     
     
     
313. KILINC YB, Kilinc E, Danis A, Hanci F, et al
     Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1alpha are elevated in pediatric migraine attacks.
     Headache. 2023 Aug 19. doi: 10.1111/head.14618.
     PubMed     Abstract available
     
     
     
314. ORNELLO R, Bruno F, Frattale I, Curcio G, et al
     White matter hyperintensities in migraine are not mediated by a dysfunction of the glymphatic system-A diffusion tensor imaging magnetic resonance imaging study.
     Headache. 2023 Aug 18. doi: 10.1111/head.14607.
     PubMed     Abstract available
     
     
     
315. QIN Z, Qu H, Liang HB, Zhou Q, et al
     Altered resting-state effective connectivity of trigeminal vascular system in migraine without aura: A spectral dynamic causal modeling study.
     Headache. 2023 Aug 7. doi: 10.1111/head.14602.
     PubMed     Abstract available
     
     
     
316. YANG L, Zhou Y, Zhang L, Wang Y, et al
     Aryl hydrocarbon receptors improve migraine-like pain behaviors in rats through the regulation of regulatory T cell/T-helper 17 cell-related homeostasis.
     Headache. 2023 Aug 4. doi: 10.1111/head.14599.
     PubMed     Abstract available
     
     
     July 2023
317. NAHMAN-AVERBUCH H, Callahan D, Darken R, Haroutounian S, et al
     Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment-A narrative review.
     Headache. 2023 Jul 31. doi: 10.1111/head.14601.
     PubMed     Abstract available
     
     
     
318. GELFAND AA, Allen IE, Grimes B, Irwin S, et al
     Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.
     Headache. 2023 Jul 19. doi: 10.1111/head.14600.
     PubMed     Abstract available
     
     
     
319. MEHNERT J, Fischer-Schulte L, May A
     Aura phenomena do not initiate migraine attacks-Findings from neuroimaging.
     Headache. 2023 Jul 14. doi: 10.1111/head.14597.
     PubMed     Abstract available
     
     
     
320. DE VRIES LENTSCH S, Perenboom MJL, Carpay JA, MaassenVanDenBrink A, et al
     Visual hypersensitivity in patients treated with anti-calcitonin gene-related peptide (receptor) monoclonal antibodies.
     Headache. 2023;63:926-933.
     PubMed     Abstract available
     
     
     
321. REIDY BL, Riddle EJ, Powers SW, Slater SK, et al
     Biopsychosocial treatment response among youth with continuous headache: A retrospective, clinic-based study.
     Headache. 2023;63:942-952.
     PubMed     Abstract available
     
     
     June 2023
322. LANE IA, Zempsky WT
     Capturing the experiences of sexual and gender minorities with migraine headache.
     Headache. 2023 Jun 27. doi: 10.1111/head.14595.
     PubMed    
     
     
     
323. JICHA CJ, Alex A, Herskovitz S, Haut SR, et al
     Migraine with prolonged aphasic aura associated with a CACNA1A mutation: A case report and narrative review.
     Headache. 2023 Jun 27. doi: 10.1111/head.14594.
     PubMed     Abstract available
     
     
     
324. NAGRI A, Patel M, Mwansisya T, Adebayo PB, et al
     Development and initial validation of the Kiswahili version of the Migraine Disability Assessment (MIDAS-K) questionnaire.
     Headache. 2023 Jun 27. doi: 10.1111/head.14592.
     PubMed     Abstract available
     
     
     
325. DANNO D, Ishizaki K, Kikui S, Takeshima T, et al
     Treatment of hemiplegic migraine with anti-calcitonin gene-related peptide monoclonal antibodies: A case series in a tertiary-care headache center.
     Headache. 2023 Jun 27. doi: 10.1111/head.14591.
     PubMed     Abstract available
     
     
     
326. BOCZARSKA-JEDYNAK M, Blumenfeld AM
     Injection technique of the upper face with onabotulinumtoxinA in chronic migraine.
     Headache. 2023 Jun 27. doi: 10.1111/head.14588.
     PubMed     Abstract available
     
     
     
327. PERETZ A, Stark-Inbar A, Harris D, Tamir S, et al
     Safety of remote electrical neuromodulation for acute migraine treatment in pregnant women: A retrospective controlled survey-study.
     Headache. 2023 Jun 19. doi: 10.1111/head.14586.
     PubMed    
     
     
     
328. RODRIGUEZ-RIVAS R, Moreno-Martinez CA, Cerqueira TL, Enriquez-Peregrino KG, et al
     Translation, cross-cultural adaptation, and validation of a Latin American Spanish version of the ID Migraine screening test.
     Headache. 2023 Jun 16. doi: 10.1111/head.14509.
     PubMed     Abstract available
     
     
     
329. MANGANO GD, Capizzi MR, Mantuano E, Veneziano L, et al
     Familial hemiplegic migraine in pediatric patients: A genetic, clinical, and follow-up study.
     Headache. 2023 Jun 16. doi: 10.1111/head.14582.
     PubMed     Abstract available
     
     
     
330. COHEN F, Bobker S
     From diet to disasters, lifestyle factors can affect headaches and migraine.
     Headache. 2023 Jun 15. doi: 10.1111/head.14500.
     PubMed    
     
     
     
331. AHMED Z, Honomichl R, Thompson SF, Cohen JM, et al
     Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
     Headache. 2023 Jun 14. doi: 10.1111/head.14527.
     PubMed     Abstract available
     
     
     
332. YU B, Hou S, Xing Y, Jia Z, et al
     Ultrasound-guided stellate ganglion block for the treatment of migraine in elderly patients: A retrospective and observational study.
     Headache. 2023 Jun 14. doi: 10.1111/head.14537.
     PubMed     Abstract available
     
     
     
333. TEPPER SJ, Lipton RB, Silberstein SD, Kudrow D, et al
     Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
     Headache. 2023 Jun 14. doi: 10.1111/head.14536.
     PubMed     Abstract available
     
     
     
334. SENG EK, Parker A, Shapiro RE, Buse DC, et al
     Living in society, living with migraine: Editorial for the 2022 Members' Choice Award paper.
     Headache. 2023 Jun 14. doi: 10.1111/head.14530.
     PubMed    
     
     
     
335. ZLOOF Y, Simchoni M, Derazne E, Tsur AM, et al
     Hypermobility spectrum disorders and active migraine in Israeli adolescents: A nationwide study.
     Headache. 2023 Jun 14. doi: 10.1111/head.14526.
     PubMed     Abstract available
     
     
     
336. ZHANG Y, Smith JH, Mullan AF, Vanmeter DE, et al
     Frequency of headache in emergency department patients with anaphylaxis: A cross-sectional study.
     Headache. 2023;63:834-838.
     PubMed     Abstract available
     
     
     
337. KARSAN N, Bose RP, O'Daly O, Zelaya F, et al
     Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labeling.
     Headache. 2023;63:771-787.
     PubMed     Abstract available
     
     
     
338. PARK SY, Kim J
     Characteristics of patients who visited emergency departments for headache in South Korea: A descriptive cross-sectional study.
     Headache. 2023;63:795-804.
     PubMed     Abstract available
     
     
     May 2023
339. SACCA F, Braca S, Sansone M, Miele A, et al
     A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
     Headache. 2023 May 31. doi: 10.1111/head.14528.
     PubMed     Abstract available
     
     
     
340. LAU CI, Chen WH, Wang HC, Walsh V, et al
     Decision-making impairment under ambiguity but not under risk may underlie medication overuse in patients with chronic migraine.
     Headache. 2023 May 26. doi: 10.1111/head.14513.
     PubMed     Abstract available
     
     
     
341. HANS A, Stonnington CM, Zhang N, Butterfield R, et al
     The impact of resilience on headache disability as measured by the Migraine Disability Assessment (MIDAS).
     Headache. 2023 May 23. doi: 10.1111/head.14518.
     PubMed     Abstract available
     
     
     
342. LIPTON RB, Sico J, Seng EK
     Migraine screening in English and Spanish.
     Headache. 2023 May 4. doi: 10.1111/head.14520.
     PubMed    
     
     
     
343. MANGRUM R, Gerstein MT, Hall CJ 3rd, Buse DC, et al
     Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine.
     Headache. 2023 May 4. doi: 10.1111/head.14521.
     PubMed     Abstract available
     
     
     
344. KELLIER DJ, de Prado BM, Haagen D, Grabner P, et al
     Validity of self-reported migraine in adolescents and children.
     Headache. 2023 May 4. doi: 10.1111/head.14498.
     PubMed     Abstract available
     
     
     
345. TEPPER SJ, Dong Y, Vincent M, Wietecha LA, et al
     Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
     Headache. 2023 May 3. doi: 10.1111/head.14494.
     PubMed     Abstract available
     
     
     
346. MEI HR, Hu YY, Kapadia S, Ouimet T, et al
     Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors.
     Headache. 2023;63:621-633.
     PubMed     Abstract available
     
     
     
347. ACKLEY E, Asamoah P, Mirsky D, White C, et al
     Dots and spots: A retrospective review of T2-hyperintense white matter lesions in pediatric patients with and without headache.
     Headache. 2023;63:611-620.
     PubMed     Abstract available
     
     
     
348. HOULE TT, Smith MR, Turner DP
     Common challenges in the development of prediction models.
     Headache. 2023;63:569-570.
     PubMed    
     
     
     
349. KATSUKI M, Tatsumoto M, Kimoto K, Iiyama T, et al
     Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross-sectional study.
     Headache. 2023;63:585-600.
     PubMed     Abstract available
     
     
     April 2023
350. WANG Z, Lin Q, Peng YB
     Multi-region local field potential signatures and brain coherence alternations in response to nitroglycerin-induced migraine attacks.
     Headache. 2023 Apr 10. doi: 10.1111/head.14506.
     PubMed     Abstract available
     
     
     
351. CHEN YJ, Hu KF, Chan C, Huang C, et al
     Association of periodontal disease with migraine: A large-scale community-based cross-sectional study.
     Headache. 2023 Apr 10. doi: 10.1111/head.14491.
     PubMed     Abstract available
     
     
     
352. CARMILLO L, Fasano A
     Fremanezumab plus plasmapheresis in a patient with chronic migraine and myasthenia gravis: Case report of an effective treatment.
     Headache. 2023 Apr 10. doi: 10.1111/head.14497.
     PubMed     Abstract available
     
     
     
353. THOMPSON AC, Goodbourn PT, Forte JD
     Perceived severity of Visual Snow Syndrome is associated with visual allodynia.
     Headache. 2023;63:494-505.
     PubMed     Abstract available
     
     
     March 2023
354. OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
     Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study.
     Headache. 2023 Mar 29. doi: 10.1111/head.14492.
     PubMed     Abstract available
     
     
     
355. DIGRE KB
     Good New? Bad News? Idiopathic intracranial hypertension and migraine.
     Headache. 2023 Mar 29. doi: 10.1111/head.14489.
     PubMed    
     
     
     
356. GRAF M, Kim E, Brewer I, Hernandez J, et al
     Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel.
     Headache. 2023 Mar 15. doi: 10.1111/head.14479.
     PubMed     Abstract available
     
     
     
357. GERSTEIN MT, Wirth RJ, Uzumcu AA, Houts CR, et al
     Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.
     Headache. 2023 Mar 10. doi: 10.1111/head.14484.
     PubMed     Abstract available
     
     
     
358. VERHAGEN IE, van der Arend BWH, van Casteren DS, le Cessie S, et al
     Sex differences in migraine attack characteristics: A longitudinal E-diary study.
     Headache. 2023;63:333-341.
     PubMed     Abstract available
     
     
     
359. KUDROW D, Dafer R, Dodick DW, Starling A, et al
     Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data.
     Headache. 2023;63:418-428.
     PubMed     Abstract available
     
     
     
360. BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
     Characterization of trigeminal C-fiber reactivity through capsaicin-induced release of calcitonin gene-related peptide.
     Headache. 2023;63:353-359.
     PubMed     Abstract available
     
     
     
361. ACKLEY E, Gibler RC, Orr SL, Powers SW, et al
     Virtual issue: Recent advances in pediatric headache: Bridging the data gap.
     Headache. 2023;63:305-306.
     PubMed    
     
     
     February 2023
362. ESTAVE PM, Margol C, Beeghly S, Anderson R, et al
     Mechanisms of mindfulness in patients with migraine: Results of a qualitative study.
     Headache. 2023 Feb 28. doi: 10.1111/head.14481.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum